Why the study?
Very short duration of dual antiplatelet therapy (≤ 3 months) had recently been proposed after PCI with DES, warranting a comparison against longer durations.
Does very short duration of dual antiplatelet therapy (≤ 3 months) reduce net adverse clinical events in patients undergoing PCI with DES compared to longer DAPT (> 3 months)?
Does very short duration of dual antiplatelet therapy (≤ 3 months) reduce net adverse clinical events in patients undergoing PCI with DES compared to longer DAPT (> 3 months)?
Very short dual antiplatelet therapy (≤ 3 months) after PCI with DES reduces net adverse clinical events and major bleeding without increasing ischemic risk compared to longer DAPT.
Answers are grounded in this paper and cite their sources.
Supports very short DAPT after DES-PCI to reduce bleeding risk; confirms net benefit of abbreviated regimens in meta-analysis.
BACKGROUND: Very short (≤ 3 months) duration of dual antiplatelet therapy (VSDAPT) has recently been proposed after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). OBJECTIVES: The aim of this systematic review and meta-analysis was to compare very short versus > 3 months' duration of dual antiplatelet treatment (DAPT) in patients undergoing PCI with DES, focusing on ischemic and bleeding events. METHODS: Three major databases (Medline, Cochrane Central Register of Controlled Trials, and Scopus) were screened for eligible randomized controlled trials (RCTs). The primary endpoint of our meta-analysis was the incidence of net adverse clinical events (NACE), as defined per trial, while secondary endpoints were major adverse cardiovascular events (MACE), all-cause and cardiovascular mortality, myocardial infarction, stroke, stent thrombosis, repeat revascularization, and major bleeding. RESULTS: We included eight RCTs with a total of 41,204 patients; 20,592 patients were allocated to VSDAPT and the remaining 20,612 patients were randomized to a longer DAPT period. The abbreviated regimen significantly reduced NACE (odds ratio [OR] 0.83, 95% confidence interval [Cl] 0.74-0.95) and major bleeding (OR 0.71, 95% Cl 0.61-0.82), without affecting mortality or ischemic events (stroke, myocardial infarction, revascularization, and stent thrombosis). CONCLUSIONS: VSDAPT significantly decreased the odds of NACEs and major bleeding by 17% and 29%, respectively, without increasing ischemic events. Thus, VSDAPT could be well tolerated and feasible after PCI with DES. CLINICAL TRIALS REGISTRATION: Open Science Framework (10.17605/OSF.IO/4H2JB) Very short-term DAPT significantly reduces NACE and major bleedings, without affecting mortality and ischemic events (MACE, MI, stroke, stent thrombosis and revascularization). CI confidence intervals, DAPT dual antiplatelet therapy, DES drug-eluting stents, MACE major adverse cardiovascular events, MI myocardial infarction, NACE net adverse clinical events, OR odds ratio, PCI percutaneous coronary interventions.
No takes yet. Share an insight, caveat, or question.
Tsigkas et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: